Cartesian Therapeutics Shares Are Trading Higher After Leerink Partners Initiated Coverage on the Stock With an Outperform Rating and Announced a $39 Price Target
在Leerink Partners以跑赢大盘的评级启动了对该股的报道并宣布了39美元的目标股价之后,Cartesian Therapeutics的股价走高
Cartesian Therapeutics Shares Are Trading Higher After Leerink Partners Initiated Coverage on the Stock With an Outperform Rating and Announced a $39 Price Target
在Leerink Partners以跑赢大盘的评级启动了对该股的报道并宣布了39美元的目标股价之后,Cartesian Therapeutics的股价走高
使用浏览器的分享功能,分享给你的好友吧